29 Results for "

FaDu cells

" in MedChemExpress (MCE) Product Catalog:
Products (29)

29 Results for "FaDu cells" in MCE Product Catalog:

26
26 Publications Verification
Cat. No.: HY-13902
CAS No.: 1232416-25-9
Purity:  99.70%
Synonyms: VE-822; VX-970; M6620
Research Areas:  

Infection Metabolic Disease Cancer

Berzosertib (VE-822) is an orally active, CNS-penetrant, and selective ATR kinase inhibitor. Berzosertib blocks ATR kinase activity, abrogates G2/M cell cycle checkpoint, impairs DNA damage repair. Berzosertib induces apoptosis, inhibnits conlony migration, inhibits cell proliferation, and activates cGAS-STING axes in cancer cells. Berzosertib can be used for the research of cancers, such as head and neck squamous cell carcinoma, and colorectal cancer .
loading...
    loading...
26
26 Publications Verification
Cat. No.: HY-13902A
CAS No.: 1428935-04-9
Synonyms: VE-822 hydrochloride; VX-970 hydrochloride; M6620 hydrochloride
Research Areas:  

Neurological Disease Cancer

Berzosertib (VE-822) hydrochloride is an orally active, CNS-penetrant, and selective ATR kinase inhibitor. Berzosertib hydrochloride blocks ATR kinase activity, abrogates G2/M cell cycle checkpoint, impairs DNA damage repair. Berzosertib hydrochloride induces apoptosis, inhibnits conlony migration, inhibits cell proliferation, and activates cGAS-STING axes in cancer cells. Berzosertib hydrochloride can be used for the research of cancers, such as head and neck squamous cell carcinoma, and colorectal cancer .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-141598
CAS No.: 2238831-60-0
Purity:  99.54%
Synonyms: DS-1062 (solution); Dato-DXd (solution)
Datopotamab deruxtecan (DS-1062) solution is a TROP2-targeted antibody-drug conjugate (ADC) with human TROP2 Kd of 0.74 nmol/L. Datopotamab deruxtecan solution consists of the antibody Datopotamab (HY-P99843) and the toxic molecule-linker conjugate Deruxtecan (HY-13631E). Datopotamab deruxtecan solution binds TROP2, triggers internalization and lysosomal trafficking and releases DXd topoisomerase I inhibitor payload. Datopotamab deruxtecan solution disrupts DNA function, induces DNA damage, apoptosis, and bystander killing of tumor microenvironment cells. Datopotamab deruxtecan solution can be used in research related to triple-negative breast cancer, gastric cancer, and non-small cell lung cancer .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-114245
CAS No.: 26046-90-2
Purity:  99.60%
Synonyms: Methylselenocysteine; Se-Methylseleno-L-cysteine
Se-Methylselenocysteine, a precursor of Methylselenol, has potent cancer chemopreventive activity and anti-oxidant activity. Se-Methylselenocysteine is orally bioavailable, and induces apoptosis .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-B1260
CAS No.: 57-09-0
Synonyms: CTAB; Cetyltrimethylammonium bromide; Hexadecyltrimethylammonium bromide
Cetrimonium bromide (CTAB), a quaternary ammonium, is an orally active cationic surfaetant. Cetrimonium bromide has toxicity and anticancer effect. Cetrimonium bromide inhibits cell migration and invasion through modulating the canonical and non-canonical TGF-β signaling pathways. Cetrimonium bromide can be used for DNA extraction .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-141598B
CAS No.: 2238831-60-0
Synonyms: DS-1062; Dato-DXd
Datopotamab deruxtecan (DS-1062) is a TROP2-targeted antibody-drug conjugate (ADC) with human TROP2 Kd of 0.74 nmol/L. Datopotamab deruxtecan consists of the antibody Datopotamab (HY-P99843) and the toxic molecule-linker conjugate Deruxtecan (HY-13631E). Datopotamab deruxtecan binds TROP2, triggers internalization and lysosomal trafficking and releases DXd topoisomerase I inhibitor payload. Datopotamab deruxtecan disrupts DNA function, induces DNA damage, apoptosis, and bystander killing of tumor microenvironment cells. Datopotamab deruxtecan can be used in research related to triple-negative breast cancer, gastric cancer, and non-small cell lung cancer .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-B0942
CAS No.: 121-54-0
Benzethonium chloride inhibits nicotinic acetylcholine receptors in human recombinant α7 and α4β2 neurons in Xenopus laevis oocytes, which has antibacterial, anticancer, antisepsis and disinfection activity. Benzethonium chloride induced Apoptosis and activated caspases in cancer cell lines. Benzethonium chloride ablates the tumor-forming ability of FaDu cells, delays the growth of xenograft tumors in vivo .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-N0757
CAS No.: 6926-14-3
8-O-Acetylharpagide is an orally active iridoid glycoside compound. 8-O-Acetylharpagide exhibits anti-aging activity at low doses and anticancer activity at high doses. 8-O-Acetylharpagide induces late-stage apoptosis and necrosis-like death in cancer cells, and downregulates anti-apoptotic proteins such as Akt, p-Akt and Bcl-2. 8-O-Acetylharpagide is mainly metabolized in rats via demethylation, hydrolysis and glucuronidation, and its active metabolites downregulate the AKT/NF-κB/MMP9 signaling axis. 8-O-Acetylharpagide exerts vasoconstrictive effects by activating vascular α-adrenoceptor .
loading...
    loading...
Cat. No.: HY-120087
CAS No.: 175205-09-1
Purity:  99.92%
Research Areas:  

Cancer

KG-548 is an ARNT/TACC3 disruptor and a HIF-1α inhibitor. KG-548 directly interferes with ARNT/TACC3 complex formation by competing with TACC3 for binding to the ARNT PAS-B domain. ARNT is the aryl hydrocarbon receptor nuclear translocator, also known as HIF-β .
loading...
    loading...
Cat. No.: HY-176761
CAS No.: 1033931-92-8
Research Areas:  

Cancer

NSC647889 is an apoptosis and autophagy inducer. NSC647889 induces apoptosis, inhibits mTOR pathway and abrogates DNA synthesis. NSC647889 triggers LC3-positive vesicle formation, modulates AKT and 4EBP1 phosphorylation and shows heightened caspase-3 activation in multicellular spheroids. NSC647889 can be used for the research of solid cancer tumour, head-neck carcinoma, and colorectal cancer .
loading...
    loading...
Cat. No.: HY-178226
CAS No.: 3003834-34-9
PBX-7016 is a DNA topoisomerase I inhibitor and DDX5 degrader. PBX-7016 induces DNA damage and downregulates Survivin, Mcl-1, and XIAP. PBX-7016 exerts a bystander killing effect. PBX-7016 can serve as an ADC payload for the synthesis of ADC. PBX-7016 is applicable to research related to head and neck cancer, non-small cell lung cancer, breast cancer, colorectal cancer, and ovarian cancer .
loading...
    loading...
Cat. No.: HY-P99719
CAS No.: 1640972-00-4
Synonyms: BAY 1129980; Anti-C4.4a antibody-drug conjugates
Research Areas:  

Cancer

Lupartumab Amadotin (BAY 1129980) is an antibody–drug conjugate (ADC) consisting of a fully human C4.4A (LYPD3)-targeting mAb (BAY 1135626) (HY-147281) conjugated to a novel, highly potent derivative of the microtubule-disrupting cytotoxic drug auristatin via a noncleavable alkyl hydrazide linker. Lupartumab Amadotin can be used for the research of non-small cell lung cancer .
loading...
    loading...
Cat. No.: HY-153067
CAS No.: 2578019-72-2
Research Areas:  

Cancer

Mal-cyclohexane-Gly-Gly-Phe-Gly-Exatecan (Compound 11) is a bioactive compound-linker conjugate for ADC. Mal-cyclohexane-Gly-Gly-Phe-Gly-Exatecan can conjugate with antibodies to form ADC (C-11) with anti-tumor activity. Exatecan is a DNA Topoisomerase I inhibitor. Mal-cyclohexane-Gly-Gly-Phe-Gly-Exatecan can be used in the research of squamous cell carcinoma, pancreatic adenocarcinoma and colorectal cancer .
loading...
    loading...
Cat. No.: HY-174803
CAS No.: 2416914-29-7
WMJ-J-09 is an HDAC inhibitor with IC50 values of 7.5 nM (HDAC1), 21.3 nM (HDAC2), 18.4 nM (HDAC3), 90.9 nM (HDAC8), 3.9 nM (HDAC6) and 8715.7 nM (HDAC4). WMJ-J-09 blocks the cell cycle and induces apoptosis in cancer cells. WMJ-J-09 induces cancer cell death through the LKB1-AMPK-p38MAPK-p63-survivin signaling cascade.WMJ-J-09 inhibits HDAC enzyme activity, leading to acetylation of key proteins and thereby regulating cancer cell death. WMJ-J-09 can be used in HCT116 cells and FaDu cells research[1][2].
loading...
    loading...
Cat. No.: HY-160438B
Target:  

Bcl-2 Family Survivin

Research Areas:  

Cancer

PBX-7011 TFA is a derivative of camptothecin (HY-16560), which inhibits expressions of the cancer related survival genes DDX5, Survivin, Mcl-1 and XIAP in cells FaDu, degrades DDX5 proteins and exhibits anticancer activity .
loading...
    loading...
Cat. No.: HY-W272058
CAS No.: 705-19-1
Target:  

Drug Derivative

Research Areas:  

Cancer

Isometronidazole is a hypoxic cell sensitizer. Isometronidazole (750 mg/kg) shows an efficacy as a hypoxic cell sensitizer in severely hypoxic FaDu tumors but not in less hypoxic GL tumors.
loading...
    loading...
Cat. No.: HY-W272058R
CAS No.: 705-19-1
Research Areas:  

Cancer

Isometronidazole (Standard) is the analytical standard of Isometronidazole. This product is intended for research and analytical applications. Isometronidazole is a hypoxic cell sensitizer. Isometronidazole (750 mg/kg) shows an efficacy as a hypoxic cell sensitizer in severely hypoxic FaDu tumors but not in less hypoxic GL tumors.
loading...
    loading...
Cat. No.: HY-114245R
CAS No.: 26046-90-2
Synonyms: Methylselenocysteine (Standard); Se-Methylseleno-L-cysteine (Standard)
Risedronic acid (Standard) is the analytical standard of Risedronic acid. This product is intended for research and analytical applications. 0
loading...
    loading...
Cat. No.: HY-114245B
CAS No.: 863394-07-4
Synonyms: Methylselenocysteine hydrochloride; Se-Methylseleno-L-cysteine hydrochloride
Se-Methylselenocysteine hydrochloride, a precursor of Methylselenol, has potent cancer chemopreventive activity and anti-oxidant activity. Se-Methylselenocysteine hydrochloride is orally bioavailable, and induces apoptosis .
loading...
    loading...
Cat. No.: HY-169134
Research Areas:  

Cancer

PROTAC 20S proteasome subunit β5 degrader 1 is a PROTAC degrader targeting the 20S proteasome subunit β5, with a DC50 of 0.11 μM. PROTAC 20S proteasome subunit β5 degrader 1 forms a ternary complex with the CRBN E3 ligase, induces ubiquitination of the 20S proteasome subunit β5, and promotes its degradation via the proteasomal pathway. PROTAC 20S proteasome subunit β5 degrader 1 disrupts cell cycle progression, promotes apoptosis, and inhibits cell proliferation and migration. PROTAC 20S proteasome subunit β5 degrader 1 exhibits significant proliferation-inhibitory activity against various tumor cells, suppresses tumor growth in in vivo xenograft models, and overcomes the resistance of multiple myeloma cells to Bortezomib (HY-10227). PROTAC 20S proteasome subunit β5 degrader 1 can be used in studies related to pharyngeal cancer and drug-resistant multiple myeloma .
loading...
    loading...